EP Patent

EP1899323A2 — Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors

Assigned to AstraZeneca AB · Expires 2008-03-19 · 18y expired

What this patent protects

This invention relates to novel compounds having the formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.

USPTO Abstract

This invention relates to novel compounds having the formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP1899323A2
Jurisdiction
EP
Classification
—
Expires
2008-03-19
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.